5.92
Wave Life Sciences Ltd stock is traded at $5.92, with a volume of 1.93M.
It is up +1.89% in the last 24 hours and up +1.54% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$5.81
Open:
$5.92
24h Volume:
1.93M
Relative Volume:
0.56
Market Cap:
$1.14B
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-5.6151
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
+3.32%
1M Performance:
+1.54%
6M Performance:
-55.69%
1Y Performance:
-29.52%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd
|
5.92 | 1.12B | 71.80M | -183.59M | -186.52M | -1.0543 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-26 | Resumed | Truist | Buy |
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
WAVE Life Sciences Ltd (WVE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
WAVE Life Sciences Ltd (WVE) Cash Flow - TradingKey
WAVE Life Sciences Ltd (WVE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WVE|WAVE Life Sciences Ltd|Price:5.810|Chg%:+0.030 - TradingKey
TradingKey - TradingKey
Wave Life Sciences Ltd. Revenue Breakdown – NASDAQ:WVE - TradingView
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
WAVE Life Sciences Ltd (WVE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Is Analyst Upgrade After Q2 Review Altering The Investment Case For Wave Life Sciences (WVE)? - simplywall.st
Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales - Yahoo Finance
Trading the Move, Not the Narrative: (WVE) Edition - Stock Traders Daily
Wave Life Sciences to report Q2 2026 financial results on July 30 - scanx.trade
Wave Life Sciences stock trades steady as genetic medicine pipeline advances after recent loss narro - Ad-hoc-news.de
Wave Life Sciences to Host Second Quarter 2026 Financial Results Webcast and Conference Call - Quiver Quantitative
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 - The Manila Times
Wave Life Sciences Ltd (WVE) News, Articles, Events & Latest Updates - Stocktwits
Wave Life Sciences to host webcast, call on second-quarter results - Bitget
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance Singapore
New Strong Buy Stocks for July 22nd - The Globe and Mail
Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In? - simplywall.st
Wave Life Sciences Ltd. (WVE) Stock Analysis: Unveiling a Potential 282.85% Upside in Biotech - DirectorsTalk Interviews
Wave Life Sciences Pte. Ltd (WVE) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill
Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
ETFs Investing in Wave Life Sciences Ltd. Stocks - TradingView
WVE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
WVE Technical Analysis & Stock Price Forecast - Intellectia AI
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued? - Sahm
Wave Life Sciences (WVE) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Wave Life Sciences court hearing set for July 14 on redomiciliation - Investing.com
Wave Life Sciences court hearing set for July 14 on redomiciliation By Investing.com - Investing.com South Africa
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - The Manila Times
Press Release: Wave Life Sciences Announces Singapore Court Hearing, to Be Held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - Moomoo
Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial - simplywall.st
Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress? - simplywall.st
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect? - Yahoo Finance
Jessica Chen - White & Case LLP
(WVE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial - Insider Monkey
Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
7 Singapore Companies That Have Listed On Nasdaq And Where They Are Now - DollarsAndSense.sg
Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning? - simplywall.st
Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to sales forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Enterprise value to EBIT forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView
Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation - Stock Titan
We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth - Moomoo
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):